Kevin Qian is a special advisor and co-founder of Yuanda. He focuses his practice on advising international companies on direct investment in China and in representing Chinese companies and high net-worth individuals investing in foreign countries. Kevin has represented hundreds of multinationals and Fortune 500 companies in transactions that have included investing in joint venture companies, establishing wholly owned companies, cross-border mergers and acquisitions, strategic alliances and venture capital and private equity investments. He has advised companies in a wide range of industries, including manufacturing, retail, energy and chemicals, health care, pharmaceuticals and food and beverages. Kevin currently serves as a member of the board and deputy secretary general of the Shanghai Venture Capital Association and is a former independent director of SAIC Motor Corporation, Ltd., China Minsheng Investment Corp., Ltd. and Shanghai Jiao Da Onlly Co., Ltd.
In 2014, he was named an arbitrator of the China International Economic and Trade Arbitration Commission.
In addition, Kevin also has held the following roles during his legal career:
- Senior legal counsel of Philips Electronics in Asia, where he was responsible for legal matters concerning Philips’ 30 wholly owned and joint venture enterprises in consumer electronic products, semiconductor, and medical device and equipment throughout the region.
- Deputy general manager and legal counsel for PepsiCo Investment China Co., Ltd., where he managed more than 40 wholly-owned and joint venture enterprises in the beverage, restaurant and snack food industries.
- Head of the Asia Pacific and China Practice Group at a leading U.S. law firm.
- Partner of the largest law firm in Shanghai, where he served as a key director of its executive committee.
- Advised a well-known U.S. electronic products company on the China component of a global merger, including due diligence, the integration of newly acquired Chinese entities, compliance issues, ongoing business operation matters and human resource issues.
- Represented a U.S.-based private equity fund in acquiring majority equity interest in a Chinese agriculture company in a USD100 million transaction; also represented the fund in acquiring majority equity interest in a Changzhou-based chemical company in a transaction with a total purchase price of RMB160 million.
- Represented a joint venture formed by a U.S. private equity fund and an Asia-based commodities firm in its investment in one of China’s largest mining companies, in the first case in which a foreign PE fund successfully exited from a Chinese domestic company through a Chinese stock market.
- Represented a Chinese state-owned venture capital company in Shanghai in a series of venture investments in a large semiconductor company, totaling more than USD125 million from A Round to E Round.
- Represented a Chinese state-owned venture capital firm in its establishment as an investment company and handled all the company’s legal matters, including assisting with the selection of target companies within and outside China, drafting legal documents and obtaining approvals from various government authorities to set up funds abroad.
- Represented an Anglo-American private equity fund in its USD23 million portfolio investment in China’s forest and farm industry, including executing transaction design, documentation and legal due diligence.
- Assisted a U.S. private equity firm in its acquisition of Chinese enterprises in various business lines, by providing comprehensive services including legal structure design, legal due diligence, and negotiation and drafting of definitive agreements, and handling post-closing issues such as actual control, shareholder information right, regulatory compliance and dispute resolution.
- Represented a Swiss-based global manufacturer of pharmaceutical products in the establishment of its active pharmaceutical ingredient (API) manufacturing plant in China, as well as in its acquisition of a Taiwan-listed pharmaceutical manufacturer.
- Assisted one of the world’s largest drug-development services companies in designing its investment strategy for the establishment of an R&D center in China, creating a structure that enabled the company to implement its near- and long-term development plans in accordance with complex Chinese regulations governing land use, foreign investment, tax and administrative law.
- Ranked among the leading lawyers in China for Corporate M&A by Chambers Global 2015 and Chambers Asia-Pacific
- Named a “Leading Talent of Independent Innovation” by Huangpu District Government in 2012
- Recognized as one of the leading lawyers in China by Asia Law Leading Lawyers from 2010 to 2015
- Recognized as one of Asia’s leading business lawyers by Asian Legal Business for his outstanding practice in corporate law—especially capital markets, corporate finance, and M&A—from 2002 to 2008
- Named as one of the “Hot 30 Lawyers” as well as one of the “Hot 100” in China by Asian Legal Business magazine in 2004 and 2005
- The first Chinese lawyer selected as Chairman of the Inter-Pacific Bar Association (IPBA) International Trade Committee in 2004
Kevin’s professional memberships include the American Bar Association, the Minnesota State Bar Association, and All China Lawyers Association. He also currently serves as a member of the board and deputy secretary general of the Shanghai Venture Capital Association and is a former independent director of SAIC Motor Corporation, Ltd., China Minsheng Investment Corp., Ltd, and Shanghai Jiao Da Onlly Co., Ltd.
Additional professional and community activities in which Kevin has been involved include serving as:
- A faculty member of the East China University of Political Science and Law
- A Standing Board Member of China Law Society Lawyers Practice Committee
- Chairman of International Law Committee of the All China Lawyers Association from 2011 to 2014
- Vice President of the Foreign Affairs & WTO Committee of the All China Lawyers Association since 2007
- Program Coordinator of IPBA from 2009 to 2011
- The first Chinese lawyer selected as Chairman of the IPBA International Trade Committee in 2004